US EditionPublished • loading... • Updated
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025
Curis, Inc. will discuss its Q3 2025 financial and operational results including progress on emavusertib, an IRAK4 inhibitor in clinical trials for blood cancers.
- On Thursday, November 6, 2025, Curis, Inc. will report third quarter 2025 financial and operating results at 4:00 p.m. ET from Lexington, Mass., NASDAQ: CRIS.
- Curis is focused on developing emavusertib , evaluated in TakeAim clinical studies for relapsed/refractory PCNSL, AML, and hrMDS, holding exclusive rights via Aurigene with Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission.
- Management will host a conference call and simultaneous webcast on November 6 at 4:30 p.m. ET, with U.S. and other-location dial-in options and a replay at www.curis.com.
- A press release outlining results will be distributed before the conference call and webcast, which will cover operational highlights, financial results and key topics, Curis said.
- View original content and multimedia via the company's PR Newswire original content link, and stakeholders can visit Curis's website for more information.
Insights by Ground AI
29 Articles
29 Articles
Montana Standard+25 Reposted by 25 other sources
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025
SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter…
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial…
Coverage Details
Total News Sources29
Leaning Left0Leaning Right1Center17Last UpdatedBias Distribution94% Center
Bias Distribution
- 94% of the sources are Center
94% Center
C 94%
Factuality
To view factuality data please Upgrade to Premium
